The duration of antidiuretic response of two desmopressin nasal sprays

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 9, 1998, Pages 494-500

  Eller, N ^a   Kollenz, C J ^a   Bauer, P ^b   Hitzenberger, G ^c  

^a Gebro Broschek GmbH   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c Gesellschaft fur Klin Pharmakologie   (Austria)

Author keywords

1 deamino 8 d arginine vasopressin; Desmopressin intranasally; Desmopressin pharmacokinetics; Urine osmolality; Urine volume

Indexed keywords

DESMOPRESSIN;

ADULT; ANTIDIURESIS; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIURESIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; MALE; NAUSEA; NORMAL HUMAN; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; URINE OSMOLALITY; URINE VOLUME;

ADMINISTRATION, INTRANASAL; ADULT; CROSS-OVER STUDIES; DEAMINO ARGININE VASOPRESSIN; HEMOSTATICS; HUMANS; MALE; OSMOLAR CONCENTRATION; URODYNAMICS;

EID: 0031710981     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Andersson KE, Arner B 1972 Effects of DDAVP, a structural analogue of vasopressin, in patients with central diabetes insipidus. Act Med Scand 192: 21-27
2. Aronson AS, Andersson KE, Bergstrand CG, Mulder J 1973 Treatment of diabetes insipidus in children with DDAVP, a synthetic analogue of vasopressin. Act Paed Scand 62: 133-140
3. Becker DJ, Foley TP 1978 1-deamino-8-D-arginine vasopressin in the treatment of central diabetes insipidus. J Pediatr 92: 1011-1015
4. Belmaker RH, Bleich A 1986 The use of desmopressin in adult enuresis. Milit Med 151: 660-662
5. Curtis JR, Donovan BA 1979 Assessment of renal concentrating ability. Br Med J 1: 304-305
6. Delin K, Aurell M, Ewald J 1978 Urinary concentration test with desmopressin. Br Med J 1: 757-758
7. Diletti E, Hauschke D, Steinijans VW 1991 Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29: 1-8
8. Dimson SW 1977 Desmopressin as a treatment for enuresis. Lancet 1: 1260
9. Du Vigneaud V, Gish DT, Katsoyannis PG 1954 A synthetic preparation possessing biological properties associated with arginine vasopressin. J Am Chem S 76: 4751-4752
10. Edwards CRW, Kitau MJ, Chard T, Besser GM 1973 Vasopressin analogue DDAVP in diabetes insipidus: clinical and laboratory studies. Br Med J 3: 375-378
11. Eller N, Kollenz CJ, Hitzenberger C 1998 A comparative study of pharmacodynamics and bioavailability of two different desmopressin nasal sprays. Int J Clin Pharmacol Ther 36: 139-145
12. Fjellestad A, Czernichow P 1986 Central diabetes insipidus in children. Acta Paediatr Scand 75: 605-610
13. Fjellestad-Paulsen A, Wille S, Harris AS 1987 Comparison of intranasal and oral desmopressin for nocturnal enuresis. Arch Dis Child 62: 674-677
14. Harris AS 1989 Clinical experience with desmopressin: Efficacy and safety in central diabetes insipidus and other conditions. J Pediatrr 114: 711-718
15. Harris AS, Hedner P, Vilhardt H 1987 Nasal administration of desmopressin by spray and drops. J Pharm Pharmacol 39: 932-934
16. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A 1977 DDAVP in haemophilia. Lancet 2: 1171-1172
17. Monson JP, Richards P 1974 Desmopressin urine concentration test. Br Med J 1: 24
18. Pedersen PS, Hejl M, Kjller SS 1985 Desamino-8-D-arginine vasopressin in childhood nocturnal enuresis. J Urol 133: 65-66
19. Radó JP, Marosi J, Borbély L, Takó J 1976 Individual differences in the antidiuretic response induced by single doses of 1-Deamino-8-D-Arginine-Vasopressin (DDAVP) in patients with pituitary diabetes insipidus. Int J Clin Pharmacol 14: 259-265
20. Richardson DW, Robinson AG 1985 Desmopressin. Ann Int Med 103: 228-239
21. Robinson AG 1976 DDAVP in the treatment of central diabetes insipidus. N Engl J Med 294: 507-511
22. Tryding N, Sterner G, Berg B, Harris A, Lundin S 1987 Subcutaneous and intranasal administration of 1-Deamino-8-d-Arginine vasopressin in the assessment of renal concentration capacity. Nephron 45: 27-30
23. Valiquette G, Herbert J, Meade-D'Alisera P 1996 Desmopressin in the management of nocturia in patients with multiple sclerosis. Arch Neurol 53: 1270-1275
24. Vilhardt H, Bie P 1984 Antidiuretic effect of perorally administered DDAVP in hydrated humans. Acta Endocrinol 105:474-476
25. Vilhardt H, Aberg M, Nilsson IM 1980 Possible use of DDAVP in coagulation disorders. In: DDAVP in bleeding disorders. In: Sutor AH (ed) Schattauer, New York, pp 36-41
26. Vilhardt H, Lundin S, Falch J 1986 Plasma kinetics of DDAVP in man. Act Pharm T 58: 379-381
27. Vilhardt H 1990 Basic pharmacology of desmopressin. Drug Invest 2: 2-8
28. Williams TDM, Dunger DB, Lyon CC, Lewis RJ, Taylor F, Lightman SL 1986 Antidiuretic effect and pharmacokinetics of oral 1-Desamino-8-D-Arginine vasopressin. 1. Studies in adults and children. J Clin Endocinol 63: 129-132